These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30181580)

  • 1. Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.
    Schechter T; Perez-Albuerne E; Lin TF; Irwin MS; Essa M; Desai AV; Frangoul H; Yanik G; Dupuis LL; Jacobsohn D; Kletzel M; Ranalli M; Soni S; Seif AE; Grupp S; Dvorak CC
    Bone Marrow Transplant; 2020 Mar; 55(3):531-537. PubMed ID: 30181580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
    Lee JL; Gooley T; Bensinger W; Schiffman K; McDonald GB
    Biol Blood Marrow Transplant; 1999; 5(5):306-15. PubMed ID: 10534061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
    Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
    Abate ME; Paioli A; Cammelli S; Cesari M; Longhi A; Palmerini E; Ferrari S; Carretta E; Picci P; Piscaglia F
    Bone Marrow Transplant; 2018 May; 53(5):591-599. PubMed ID: 29335623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation.
    Salman B; Al-Khabori M; Al-Huneini M; Al-Rawas A; Dennison D; Al-Za'abi M
    Int J Hematol; 2020 Aug; 112(2):210-216. PubMed ID: 32468179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
    Song GY; Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS
    Leuk Lymphoma; 2020 Nov; 61(11):2714-2721. PubMed ID: 32580672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.
    Granger MM; Naranjo A; Bagatell R; DuBois SG; McCune JS; Tenney SC; Weiss BD; Mosse YP; Asgharzadeh S; Grupp SA; Hogarty MD; Gastier-Foster JM; Mills D; Shulkin BL; Parisi MT; London WB; Han-Chang J; Panoff J; von Allmen D; Jarzembowski JA; Park JR; Yanik GA
    Transplant Cell Ther; 2021 Jun; 27(6):490.e1-490.e8. PubMed ID: 33823167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
    Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children.
    Philippe M; Neely M; Rushing T; Bertrand Y; Bleyzac N; Goutelle S
    Bone Marrow Transplant; 2019 Mar; 54(3):448-457. PubMed ID: 30108322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children.
    Lapierre V; Mahé C; Aupérin A; Stambouli F; Oubouzar N; Tramalloni D; Benhamou E; Tiberghien P; Hartmann O
    Transplantation; 2005 Aug; 80(3):314-9. PubMed ID: 16082325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
    Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
    Roeker LE; Kim HT; Glotzbecker B; Nageshwar P; Nikiforow S; Koreth J; Armand P; Cutler C; Alyea EP; Antin JH; Richardson PG; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):137-144. PubMed ID: 30081073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
    Styler MJ; Crilley P; Biggs J; Moul J; Copelan E; Topolsky D; Avalos B; Penza S; Sabol P; Downs K; Szer J; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Jul; 18(1):171-6. PubMed ID: 8832011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.
    Faraci M; Bertaina A; Luksch R; Calore E; Lanino E; Saglio F; Prete A; Menconi M; De Simone G; Tintori V; Cesaro S; Santarone S; Orofino MG; Locatelli F; Zecca M
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):313-320. PubMed ID: 30266674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
    Desai AV; Seif AE; Li Y; Getz K; Fisher BT; Huang V; Mante A; Aplenc R; Bagatell R
    Pediatr Blood Cancer; 2016 May; 63(5):901-7. PubMed ID: 26797923
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Giardino S; Piccardo A; Conte M; Puntoni M; Bertelli E; Sorrentino S; Montera M; Risso M; Caviglia I; Altrinetti V; Lanino E; Faraci M; Garaventa A
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28775. PubMed ID: 33099289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
    French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
    Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.